Expertise in
11
conditions

Dr. Sunil Nagpal

Hematology
Bronson Oncology & Hematology Specialists-Kalamazoo
805 John St, 
Kalamazoo, MI 
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
Bronson Oncology & Hematology Specialists-Kalamazoo
805 John St, 
Kalamazoo, MI 

Overview

Sunil Nagpal is a Hematologist practicing medicine in Kalamazoo, Michigan.

Dr. Nagpal is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Large-Cell Immunoblastic Lymphoma, ALK-Positive Non-Small Cell Lung Cancer, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 15 clinical trials. Dr. Nagpal is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MI

Hospital Affiliations

Bronson Lakeview Hospital
Bronson Battle Creek Hospital
Bronson South Haven Hospital
Bronson Methodist Hospital
Borgess Medical Center

Languages Spoken

English
Hindi
Punjabi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Bronson Oncology & Hematology Specialists-Kalamazoo
805 John St, Kalamazoo, MI 49001

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Unknown
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

27 Total Publications

Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset.
Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset.
Journal: Science advances
Published: September 25, 2024
Similar Doctors
Expertise in
42
conditions
Expertise in
42
conditions
Referral may be required

Bronson Oncology & Hematology Specialists-Kalamazoo

805 John St, 
Kalamazoo, MI 
 (0.1 miles away)
269-286-7170
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Omaira is a Hematologist practicing medicine in Kalamazoo, Michigan. Dr. Omaira is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL). Dr. Omaira is currently accepting new patients.

Expertise in
32
conditions
Dr. Sabet M. Siddiqui
Hematology | Oncology
Expertise in
32
conditions
Dr. Sabet M. Siddiqui
Hematology | Oncology
Referral may be required

Bronson Methodist Hospital

805 John St, 
Kalamazoo, MI 
 (0.1 miles away)
269-286-7170
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sabet Siddiqui is a Hematologist and an Oncologist practicing medicine in Kalamazoo, Michigan. Dr. Siddiqui is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Familial Colorectal Cancer. Dr. Siddiqui is currently accepting new patients.

Expertise in
73
conditions
Dr. Latha S. Polavaram
Hematology | Hematology Oncology | Oncology
Expertise in
73
conditions
Dr. Latha S. Polavaram
Hematology | Hematology Oncology | Oncology
Referral may be required
Before you request

The Cancer & Hematology Centers - Foremost Drive Ste 200

5800 Foremost Drive Southeast, Suite 200, 
Grand Rapids, MI 
 (44.6 miles away)
616-389-1800
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Latha Polavaram is a Hematologist and a Hematologist Oncology provider practicing medicine in Grand Rapids, Michigan. Dr. Polavaram is highly rated in 73 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Aspiration. Dr. Polavaram is board certified in American Board Of Internal Medicine. Dr. Polavaram is currently accepting new patients.

Frequently Asked Questions about Dr. Sunil Nagpal

How do I make an appointment with Dr. Sunil Nagpal?

You can book an appointment with Dr. Sunil Nagpal by calling their office at 269-286-7170. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sunil Nagpal a top-rated expert for Philadelphia-Negative Chronic Myeloid Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sunil Nagpal is classified as an Distinguished expert for Philadelphia-Negative Chronic Myeloid Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sunil Nagpal specialize in?

While Dr. Sunil Nagpal is a Hematology, they have specific expertise in Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), and Large-Cell Immunoblastic Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sunil Nagpal participate in research or clinical trials?

Yes. Dr. Sunil Nagpal has published 27 articles and abstracts on conditions like Philadelphia-Negative Chronic Myeloid Leukemia. You can view a list of Dr. Sunil Nagpal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sunil Nagpal accept my insurance?

Dr. Sunil Nagpal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 269-286-7170 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nagpal's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile